Esumi, Hiroyasu

Antitumor activity of pyrvinium pamoate, 6‐(dimethylamino)‐2‐[2‐(2,5‐dimethyl‐1‐phenyl‐1 H‐pyrrol‐3‐yl)ethenyl]‐1‐methyl‐quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation

Esumi, H., Lu, J., Kurashima, Y., & Hanaoka, T. (2004) · Cancer Science

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 127

Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle

Koh, H.-J., Toyoda, T., Fujii, N., Jung, M. M., Rathod, A., Middelbeek, R. J.-W., Lessard, S. J., Treebak, J. T., Tsuchihara, K., Esumi, H., et al. (2010) · Proceedings of the National Academy of Sciences

Metabolism, Diabetes, and CancerAdipose Tissue and Metabolism

Cited by 94

An anticancer agent, pyrvinium pamoate inhibits the NADH–fumarate reductase system—a unique mitochondrial energy metabolism in tumour microenvironments

Tomitsuka, E., Kita, K., & Esumi, H. (2012) · The Journal of Biochemistry

Cancer, Hypoxia, and MetabolismCancer and biochemical research

Cited by 79

Thymidine catabolism as a metabolic strategy for cancer survival

Tabata, S., Yamamoto, M., Goto, H., Hirayama, A., Ohishi, M., Kuramoto, T., Mitsuhashi, A., Ikeda, R., Haraguchi, M., Kawahara, K., et al. (2017) · Cell Reports

Cancer, Hypoxia, and MetabolismBiochemical and Molecular Research

Cited by 68

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 65